Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 67 | 2024 | 1505 | 7.720 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 47 | 2024 | 1427 | 7.260 |
Why?
|
Antigens, CD19 | 40 | 2024 | 437 | 5.510 |
Why?
|
Lymphoma, Follicular | 14 | 2024 | 460 | 5.120 |
Why?
|
Biological Products | 29 | 2024 | 937 | 3.590 |
Why?
|
Lymphoma, B-Cell | 10 | 2024 | 945 | 3.100 |
Why?
|
Lymphoma, Non-Hodgkin | 9 | 2022 | 1376 | 2.820 |
Why?
|
Lymphoma, Mantle-Cell | 10 | 2023 | 238 | 2.410 |
Why?
|
Neurotoxicity Syndromes | 10 | 2023 | 303 | 2.280 |
Why?
|
Receptors, Antigen, T-Cell | 11 | 2024 | 2568 | 1.630 |
Why?
|
Hematopoietic Stem Cell Transplantation | 17 | 2024 | 5709 | 1.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 26 | 2024 | 11843 | 1.240 |
Why?
|
Lymphoma | 9 | 2024 | 1907 | 1.190 |
Why?
|
T-Lymphocytes | 20 | 2024 | 10273 | 1.110 |
Why?
|
Hematology | 2 | 2021 | 244 | 1.100 |
Why?
|
Stem Cell Transplantation | 11 | 2023 | 1602 | 0.940 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2024 | 180 | 0.810 |
Why?
|
Hematologic Neoplasms | 7 | 2022 | 1905 | 0.780 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2023 | 220 | 0.770 |
Why?
|
Neoplasm Recurrence, Local | 16 | 2024 | 9425 | 0.700 |
Why?
|
Transplantation, Autologous | 16 | 2023 | 2126 | 0.670 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 9 | 2024 | 1644 | 0.660 |
Why?
|
Antibodies, Bispecific | 2 | 2020 | 204 | 0.640 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1734 | 0.570 |
Why?
|
Central Nervous System Neoplasms | 2 | 2024 | 928 | 0.550 |
Why?
|
Resorcinols | 1 | 2016 | 41 | 0.540 |
Why?
|
B-Cell Activating Factor | 2 | 2014 | 116 | 0.530 |
Why?
|
Humans | 138 | 2024 | 768451 | 0.520 |
Why?
|
Isoxazoles | 1 | 2016 | 233 | 0.480 |
Why?
|
Cyclophosphamide | 7 | 2024 | 2224 | 0.470 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2016 | 423 | 0.440 |
Why?
|
Lymphoproliferative Disorders | 2 | 2023 | 531 | 0.440 |
Why?
|
Vidarabine | 4 | 2024 | 337 | 0.430 |
Why?
|
Hypotension | 1 | 2019 | 888 | 0.430 |
Why?
|
Transplantation Conditioning | 3 | 2022 | 1598 | 0.400 |
Why?
|
Transplantation, Homologous | 7 | 2023 | 4834 | 0.400 |
Why?
|
Burkitt Lymphoma | 1 | 2014 | 336 | 0.390 |
Why?
|
Graft vs Host Disease | 4 | 2021 | 3042 | 0.390 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2014 | 290 | 0.390 |
Why?
|
Leukemia, B-Cell | 1 | 2011 | 86 | 0.380 |
Why?
|
Lymphoma, T-Cell, Peripheral | 2 | 2023 | 126 | 0.370 |
Why?
|
Cost-Benefit Analysis | 1 | 2024 | 5532 | 0.370 |
Why?
|
Watchful Waiting | 1 | 2015 | 496 | 0.360 |
Why?
|
Pyrazoles | 3 | 2019 | 2024 | 0.360 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2021 | 5342 | 0.340 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13708 | 0.340 |
Why?
|
Immunotherapy | 3 | 2023 | 4728 | 0.330 |
Why?
|
Vincristine | 3 | 2024 | 1039 | 0.330 |
Why?
|
Congresses as Topic | 4 | 2023 | 810 | 0.320 |
Why?
|
Hodgkin Disease | 3 | 2022 | 1386 | 0.320 |
Why?
|
Cord Blood Stem Cell Transplantation | 1 | 2011 | 305 | 0.320 |
Why?
|
Tumor Microenvironment | 5 | 2023 | 3939 | 0.310 |
Why?
|
Pyrimidines | 3 | 2019 | 3050 | 0.310 |
Why?
|
Survival Analysis | 9 | 2023 | 10125 | 0.310 |
Why?
|
B-Lymphocytes | 4 | 2019 | 4781 | 0.310 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 695 | 0.310 |
Why?
|
Adult | 49 | 2024 | 223542 | 0.300 |
Why?
|
Tumor Escape | 2 | 2021 | 374 | 0.300 |
Why?
|
Adenine | 4 | 2024 | 993 | 0.290 |
Why?
|
Aged | 46 | 2024 | 171520 | 0.290 |
Why?
|
Prednisone | 3 | 2024 | 1568 | 0.280 |
Why?
|
Organ Transplantation | 2 | 2023 | 1177 | 0.280 |
Why?
|
Immunologic Factors | 2 | 2019 | 1600 | 0.270 |
Why?
|
Middle Aged | 49 | 2024 | 223418 | 0.270 |
Why?
|
Recurrence | 7 | 2021 | 8510 | 0.270 |
Why?
|
Cancer Vaccines | 2 | 2024 | 1044 | 0.270 |
Why?
|
Disease Management | 3 | 2020 | 2533 | 0.270 |
Why?
|
Quinazolinones | 2 | 2019 | 222 | 0.260 |
Why?
|
Retrospective Studies | 26 | 2024 | 81834 | 0.250 |
Why?
|
Doxorubicin | 3 | 2024 | 2229 | 0.240 |
Why?
|
Piperidines | 4 | 2024 | 1664 | 0.240 |
Why?
|
Male | 52 | 2024 | 364781 | 0.230 |
Why?
|
Purines | 2 | 2019 | 614 | 0.230 |
Why?
|
Female | 54 | 2024 | 396943 | 0.220 |
Why?
|
Adrenal Cortex Hormones | 3 | 2024 | 1891 | 0.220 |
Why?
|
Genomics | 1 | 2019 | 5909 | 0.210 |
Why?
|
Standard of Care | 2 | 2024 | 571 | 0.210 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 8559 | 0.210 |
Why?
|
Polydeoxyribonucleotides | 1 | 2023 | 136 | 0.200 |
Why?
|
Immunoconjugates | 2 | 2020 | 968 | 0.200 |
Why?
|
Treatment Outcome | 18 | 2024 | 65409 | 0.200 |
Why?
|
Receptor Aggregation | 2 | 1998 | 72 | 0.200 |
Why?
|
Sulfonamides | 2 | 2022 | 1988 | 0.190 |
Why?
|
Cell Count | 2 | 2022 | 1835 | 0.190 |
Why?
|
Tolnaftate | 1 | 2020 | 2 | 0.190 |
Why?
|
Anthracyclines | 1 | 2023 | 286 | 0.190 |
Why?
|
Antibodies, Monoclonal | 4 | 2023 | 9263 | 0.180 |
Why?
|
Histiocytes | 1 | 2021 | 98 | 0.180 |
Why?
|
Graft Survival | 1 | 2011 | 3890 | 0.180 |
Why?
|
Receptors, Cholinergic | 2 | 1998 | 244 | 0.180 |
Why?
|
Leukoencephalopathies | 1 | 2024 | 261 | 0.180 |
Why?
|
Neoplasm Proteins | 3 | 2021 | 3611 | 0.170 |
Why?
|
Germany | 1 | 2022 | 882 | 0.170 |
Why?
|
Models, Economic | 1 | 2024 | 717 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 631 | 0.170 |
Why?
|
Geological Phenomena | 1 | 2019 | 11 | 0.170 |
Why?
|
Cytarabine | 3 | 2020 | 697 | 0.170 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2023 | 679 | 0.170 |
Why?
|
Agrin | 2 | 1998 | 75 | 0.160 |
Why?
|
Antigens, CD20 | 1 | 2020 | 199 | 0.160 |
Why?
|
Immunity, Innate | 1 | 2011 | 3080 | 0.160 |
Why?
|
United States | 8 | 2024 | 73121 | 0.160 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 110 | 0.160 |
Why?
|
Prognosis | 12 | 2023 | 30028 | 0.160 |
Why?
|
Azepines | 1 | 2020 | 329 | 0.160 |
Why?
|
Neoplasm, Residual | 5 | 2023 | 1014 | 0.160 |
Why?
|
Ambulances | 1 | 2019 | 93 | 0.150 |
Why?
|
Patient Selection | 3 | 2020 | 4266 | 0.150 |
Why?
|
Oligonucleotides | 1 | 2021 | 564 | 0.150 |
Why?
|
Etoposide | 2 | 2022 | 640 | 0.150 |
Why?
|
Hospitals | 2 | 2023 | 3906 | 0.150 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3619 | 0.150 |
Why?
|
Clinical Trials as Topic | 4 | 2024 | 8051 | 0.150 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2022 | 480 | 0.140 |
Why?
|
Ferritins | 1 | 2020 | 601 | 0.140 |
Why?
|
Antifungal Agents | 1 | 2022 | 761 | 0.140 |
Why?
|
Mutation, Missense | 2 | 2016 | 2594 | 0.140 |
Why?
|
Cardiovascular Agents | 1 | 2023 | 849 | 0.140 |
Why?
|
BRCA2 Protein | 1 | 2022 | 802 | 0.140 |
Why?
|
Adoptive Transfer | 1 | 2019 | 825 | 0.140 |
Why?
|
Follow-Up Studies | 9 | 2024 | 39430 | 0.140 |
Why?
|
Survival Rate | 6 | 2021 | 12875 | 0.140 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2020 | 325 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 190 | 0.130 |
Why?
|
Leukemia, Hairy Cell | 1 | 2016 | 82 | 0.130 |
Why?
|
Radioimmunotherapy | 1 | 2016 | 93 | 0.130 |
Why?
|
Cytoskeletal Proteins | 2 | 1998 | 1337 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1381 | 0.130 |
Why?
|
Pyrazines | 1 | 2021 | 1206 | 0.130 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
BRCA1 Protein | 1 | 2022 | 1158 | 0.120 |
Why?
|
Salvage Therapy | 3 | 2021 | 1277 | 0.120 |
Why?
|
Aged, 80 and over | 15 | 2024 | 59680 | 0.120 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2016 | 333 | 0.120 |
Why?
|
Ifosfamide | 1 | 2014 | 234 | 0.110 |
Why?
|
DNA | 2 | 2021 | 7213 | 0.110 |
Why?
|
Safety | 1 | 2018 | 1159 | 0.110 |
Why?
|
Consensus | 1 | 2023 | 3207 | 0.110 |
Why?
|
Prospective Studies | 6 | 2023 | 54914 | 0.110 |
Why?
|
Tumor Burden | 2 | 2020 | 1909 | 0.110 |
Why?
|
Disease-Free Survival | 6 | 2023 | 6856 | 0.110 |
Why?
|
Bone Marrow | 1 | 2023 | 2929 | 0.110 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 210 | 0.110 |
Why?
|
Switzerland | 2 | 2023 | 322 | 0.100 |
Why?
|
Electroencephalography | 3 | 2023 | 6309 | 0.100 |
Why?
|
Amino Acid Substitution | 1 | 2016 | 1744 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1781 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 3 | 2023 | 1855 | 0.100 |
Why?
|
Lymphocyte Count | 1 | 2014 | 793 | 0.100 |
Why?
|
Neutropenia | 3 | 2022 | 892 | 0.090 |
Why?
|
Nervous System Diseases | 2 | 2019 | 1668 | 0.090 |
Why?
|
Risk Factors | 7 | 2023 | 74915 | 0.090 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2834 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 998 | 0.090 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1998 | 1628 | 0.090 |
Why?
|
Thalidomide | 1 | 2016 | 885 | 0.090 |
Why?
|
Pilot Projects | 1 | 2024 | 8730 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2016 | 2434 | 0.090 |
Why?
|
Membrane Glycoproteins | 2 | 1998 | 3713 | 0.090 |
Why?
|
Heart Diseases | 1 | 2023 | 2816 | 0.090 |
Why?
|
Young Adult | 10 | 2024 | 60045 | 0.090 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 263 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1409 | 0.080 |
Why?
|
Monocytes | 1 | 2019 | 2591 | 0.080 |
Why?
|
Interleukin-6 | 1 | 2019 | 3234 | 0.080 |
Why?
|
Remission Induction | 3 | 2021 | 2408 | 0.080 |
Why?
|
Terminal Care | 1 | 2021 | 1773 | 0.080 |
Why?
|
Translocation, Genetic | 1 | 2014 | 1395 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2020 | 5808 | 0.080 |
Why?
|
Proteins | 2 | 2020 | 6008 | 0.080 |
Why?
|
Comorbidity | 1 | 2023 | 10601 | 0.080 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3854 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 2056 | 0.080 |
Why?
|
Positron-Emission Tomography | 4 | 2024 | 6657 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2022 | 4642 | 0.070 |
Why?
|
Leukemia | 1 | 2016 | 1527 | 0.070 |
Why?
|
Methotrexate | 1 | 2014 | 1722 | 0.070 |
Why?
|
Neoplasms | 3 | 2022 | 22386 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1943 | 0.070 |
Why?
|
Chronic Disease | 2 | 2014 | 9382 | 0.070 |
Why?
|
HLA Antigens | 2 | 2011 | 1338 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 958 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2019 | 3826 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5709 | 0.060 |
Why?
|
Steroids | 1 | 2010 | 937 | 0.060 |
Why?
|
Research Design | 2 | 2018 | 6217 | 0.060 |
Why?
|
Immunoglobulin Heavy Chains | 2 | 2019 | 648 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4906 | 0.060 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4419 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5192 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4861 | 0.060 |
Why?
|
Melphalan | 2 | 2022 | 420 | 0.060 |
Why?
|
Incidence | 1 | 2022 | 21552 | 0.060 |
Why?
|
Killer Cells, Natural | 1 | 2011 | 2209 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 144 | 0.050 |
Why?
|
Dystroglycans | 2 | 1998 | 62 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2022 | 185 | 0.050 |
Why?
|
Busulfan | 1 | 2022 | 259 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 10358 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7605 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2013 | 11249 | 0.050 |
Why?
|
Adolescent | 6 | 2020 | 89168 | 0.050 |
Why?
|
Antigens, CD | 1 | 2011 | 4029 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2004 | 618 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2023 | 2910 | 0.040 |
Why?
|
Mice | 6 | 2024 | 82045 | 0.040 |
Why?
|
North America | 1 | 2023 | 1292 | 0.040 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 17149 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 573 | 0.040 |
Why?
|
Societies, Medical | 2 | 2024 | 3955 | 0.040 |
Why?
|
Leukapheresis | 1 | 2020 | 150 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4572 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2024 | 12450 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9642 | 0.040 |
Why?
|
Safety-Based Drug Withdrawals | 1 | 2019 | 36 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 601 | 0.040 |
Why?
|
Antigens | 1 | 2024 | 1443 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 326 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2022 | 592 | 0.040 |
Why?
|
Tissue Distribution | 2 | 2020 | 2298 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 714 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2022 | 755 | 0.040 |
Why?
|
Nepal | 1 | 2019 | 301 | 0.040 |
Why?
|
Tuberculosis | 1 | 2010 | 2030 | 0.040 |
Why?
|
rac GTP-Binding Proteins | 1 | 1998 | 163 | 0.040 |
Why?
|
Uterine Neoplasms | 1 | 2006 | 1422 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2020 | 890 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3439 | 0.040 |
Why?
|
Animals | 8 | 2024 | 169418 | 0.040 |
Why?
|
src Homology Domains | 1 | 1998 | 362 | 0.040 |
Why?
|
Binding, Competitive | 1 | 1998 | 1144 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6537 | 0.030 |
Why?
|
Laminin | 1 | 1998 | 407 | 0.030 |
Why?
|
Death | 1 | 2021 | 683 | 0.030 |
Why?
|
Litter Size | 1 | 1996 | 49 | 0.030 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 463 | 0.030 |
Why?
|
Central Nervous System | 1 | 2023 | 1348 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 499 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2228 | 0.030 |
Why?
|
Age Factors | 3 | 2019 | 18478 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2020 | 746 | 0.030 |
Why?
|
Signal Transduction | 1 | 1998 | 23638 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 354 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 230 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2016 | 354 | 0.030 |
Why?
|
Hepatitis, Autoimmune | 1 | 2016 | 173 | 0.030 |
Why?
|
Dexamethasone | 1 | 2021 | 1965 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 369 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 716 | 0.030 |
Why?
|
Antilymphocyte Serum | 1 | 1995 | 491 | 0.030 |
Why?
|
Muscles | 1 | 1998 | 1582 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1526 | 0.030 |
Why?
|
Interleukins | 1 | 2017 | 792 | 0.030 |
Why?
|
Platelet Transfusion | 1 | 1995 | 301 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2017 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5887 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1839 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2399 | 0.020 |
Why?
|
Isoantibodies | 1 | 1995 | 682 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3212 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4041 | 0.020 |
Why?
|
Heparin | 1 | 1998 | 1636 | 0.020 |
Why?
|
Mutation | 3 | 2022 | 30243 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3941 | 0.020 |
Why?
|
Phosphorylation | 2 | 1998 | 8332 | 0.020 |
Why?
|
Disease Progression | 3 | 2013 | 13655 | 0.020 |
Why?
|
Heart Failure | 2 | 2023 | 11857 | 0.020 |
Why?
|
Stem Cells | 1 | 2022 | 3538 | 0.020 |
Why?
|
Stroke Volume | 1 | 2023 | 5620 | 0.020 |
Why?
|
Seizures | 1 | 2022 | 2996 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2964 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10784 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 1998 | 2819 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9361 | 0.020 |
Why?
|
Child | 3 | 2019 | 80863 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3901 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 41797 | 0.020 |
Why?
|
Logistic Models | 1 | 2022 | 13324 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 1996 | 2243 | 0.020 |
Why?
|
Bone Marrow Transplantation | 1 | 1995 | 2702 | 0.020 |
Why?
|
Genotype | 1 | 2022 | 13047 | 0.020 |
Why?
|
Cell Lineage | 1 | 2016 | 2575 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3237 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1881 | 0.020 |
Why?
|
Swine | 1 | 1996 | 5996 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 1998 | 4534 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2546 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7863 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10647 | 0.020 |
Why?
|
Thiotepa | 1 | 2004 | 66 | 0.010 |
Why?
|
Carrier Proteins | 1 | 1998 | 4948 | 0.010 |
Why?
|
Blood Platelets | 1 | 1995 | 2485 | 0.010 |
Why?
|
Cell Line | 1 | 1998 | 15609 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3665 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3123 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 2006 | 1123 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5367 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2006 | 1840 | 0.010 |
Why?
|
Carboplatin | 1 | 2004 | 798 | 0.010 |
Why?
|
Membrane Proteins | 1 | 1998 | 7895 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10865 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7575 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9507 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 40271 | 0.010 |
Why?
|
Infant | 2 | 2019 | 36497 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-crk | 1 | 1998 | 13 | 0.010 |
Why?
|
Child, Preschool | 2 | 2019 | 42623 | 0.010 |
Why?
|
Son of Sevenless Proteins | 1 | 1998 | 27 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 36840 | 0.010 |
Why?
|
Phenotype | 1 | 2016 | 16712 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 30179 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2004 | 21156 | 0.010 |
Why?
|
Paclitaxel | 1 | 2004 | 1737 | 0.010 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1996 | 767 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15965 | 0.010 |
Why?
|
Histocompatibility | 1 | 1995 | 322 | 0.010 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 1998 | 572 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1421 | 0.010 |
Why?
|
HeLa Cells | 1 | 1998 | 3090 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14728 | 0.010 |
Why?
|
Blotting, Western | 1 | 1998 | 5042 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1996 | 2342 | 0.010 |
Why?
|
Cell Separation | 1 | 1995 | 1726 | 0.010 |
Why?
|
Genetic Markers | 1 | 1996 | 2604 | 0.010 |
Why?
|
Leukocytes | 1 | 1995 | 2030 | 0.000 |
Why?
|